永利yl23411(中国)股份有限公司

Shize's Development History

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. was founded by Dr. LI Xiang after his return to China. The company focuses on the development of clinical-grade iPS-derived cell therapies for treatment of major or critical neurological diseases such as Parkinson’s disease that have no substantial clinical solutions. It has completed multiple rounds of hundred-million-RMB financing led by Qiming Venture Partners, Lilly Asia Ventures, Sequoia China (HongShan), and more.

Xellsmart has set up a world-class full-time team with strong industry expertise (dubbed a “Jiangsu Entrepreneurship and Innovation Model” and “Suzhou Leading Talent Enterprise”). XellSmart has independently constructed and is operating a 5000m²+ R&D center, a B+A grade GMP base and a quality control center. It has completed the core CMC development of R&D pipelines for a number of clinical-grade iPS-derived cell therapies, and established an end-to-end clinical-grade preparation process and quality control system. It has also completed formal registration and clinical batch production of a variety of GMP-grade iPS-derived subtypes of neuro-progenitor cell therapy products.

Patent

Patent Down to earth, Look up at the starry sky

Article

The beginning is the decisive battle, the beginning is the sprint

Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency: 2017-04
Yang Y, Liu B, Xu J, Wang J, Wu J, Shi C, Xu Y, Dong J, Wang C, Lai W, Zhu J, Xiong L, Zhu D, Li X, Yang W, Yamauchi T, Sugawara A, Li Z, Sun F, Li X, Li C, He A, Du Y, Wang T, Zhao C, Li H, Chi X, Zhang H, Liu Y, Li C, Duo S, Yin M, Shen H, Belmonte JCI, Deng H. Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency. Cell. 2017 Apr 6;169(2):243-257.e25. doi: 10.1016/j.cell.2017.02.005. PMID: 28388409; PMCID: PMC5679268.

Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons: 2015-08
Li X, Zuo X, Jing J, Ma Y, Wang J, Liu D, Zhu J, Du X, Xiong L, Du Y, Xu J, Xiao X, Wang J, Chai Z, Zhao Y, Deng H. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell. 2015 Aug 6;17(2):195-203. doi: 10.1016/j.stem.2015.06.003. PMID: 26253201.

Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State: 2017-08
Li X, Liu D, Ma Y, Du X, Jing J, Wang L, Xie B, Sun D, Sun S, Jin X, Zhang X, Zhao T, Guan J, Yi Z, Lai W, Zheng P, Huang Z, Chang Y, Chai Z, Xu J, Deng H. Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State. Cell Stem Cell. 2017 Aug 3;21(2):264-273.e7. doi: 10.1016/j.stem.2017.05.019. Epub 2017 Jun 22. PMID: 28648365.

Team

In 2021, Dr. Li Xiang took the lead in founding XellSmart, serving as the CEO and CSO. It united Dr. Xiao, Dr. Yan, Manager Qiu and brought together Dr. Chen, Dr. Huang, Dr. Zhu, and VP Yao, a group of experts from science and industry. At present, there are nearly 60 full-time employees, 10 Ph.D./post-doctoral fellows, and more than 65% of the postgraduates with master's degree or above.

Li Xiang (Alias: Xiang Ye)

Founder, Chairman, CEO and CSO of Shize Biopharmaceutical Co., Ltd

Ph.D. in Life Sciences, Peking University
Postdoc at the University of Wisconsin-Madison
Vice Chairman of the Eighth Council of Jiangsu Biotechnology Association
Senior Engineer of Biomedical Engineering, Suzhou City, Jiangsu Province
Suzhou Industrial Park Technology Leading Talent
2021 Golden Award 30 Outstanding Young Innovators in China
Former Senior Scientist of Sana Biotechnology (NASDAQ: SANA)

Angel round investment team

Top investment team working side by side with XellSmart Bio

FreesFund

FREES We firmly believe that being
right is more important than being
easy
FreesFund
Qiming Venture Partners

Enlighten the public with wisdom
and learn with diligence。
Qiming Venture Partners
Lilly Asia Ventures

We fight disease, save lives and
improve human health Provide
industry experience, global
resources and long-term capital.
Lilly Asia Ventures
Sequoia China

Sequoia China, the entrepreneur
behind the entrepreneur, is
committed to discovering and
cultivating [towering trees] in the
industry.
Sequoia China
TEDA Venture Capital

TEDA Tech We believe that
technology creates value.
TEDA Venture Capital
YuanBio Venture Capital

professional focus, steady and
pragmatic.
YuanBio Venture Capital
NEXT Capital

Innovator's first money
Discover the Next Big Thing.
NEXT Capital
Tao Capital

Focus on medical and health
investment to promote the
development of life sciences.
Tao Capital

Culture

Patients first, "Blade" second, shareholders third

Development History

more

In January 2022: In January 2022, XellSmart completed a Pre-A+ round of financing of nearly 100 million RMB.

In January 2022: In January 2022, XellSmart won the 2021 bioBAY "Growth Award".

In December 2021: In December 2021, XellSmart won the winning project of the National Disruptive Technology Innovation Competition.

In December 2021: In December 2021, XellSmart won the Golden Award and the Most Growing Innovative Company in 2021.

In December 2021: In December 2021, Dr. Li Xiang, founder and chairman of XellSmart, was awarded the Golden Award · 2021 China's 30 Outstanding Young Innovators

In October 2021: In October 2021, XellSmart was awarded the 2021 Top 50 Most Innovative Chinese Biopharmaceutical Enterprises.

In September 2021: In September 2021, XellSmart won the first prize in the final of the first Sino-Russian Youth Innovation, Entrepreneurship and Creativity Competition in the pharmaceutical and health industry.

In September 2021: In September 2021, XellSmart biology completed nearly 100 million yuan of pre-A round of financing.

In July 2021: In July 2021, XellSmart was elected as the executive vice-chairman unit of Jiangsu Biotechnology Association.

In June 2021: In June 2021, XellSmart won the excellent project (the highest award) of the Zhangjiang Cell Industry International Summit Roadshow.